treatment strategy Included: hydroxychloroquine, naproxen, and oseltamivir for outpatient patients with Covid 19

Evaluation of treatment strategy Included : hydroxychloroquine ,naproxen and oseltamivir for outpatient patients with Covid 19

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201202049566N1

Enrollment

150

Registered

2021-01-22

Start date

2020-02-20

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: The patient is quarantined at home for two weeks and uses two drugs, naproxen 500 mg twice daily, hydroxychloroquine 200 mg twice daily, and oseltamivir 75 mg twice

Eligibility

Sex/Gender

All

Age

12 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with Covid 19 with concurrent disease confirmation Positive PCR test Bilateral lung involvement Having symptoms of the disease Oxygen saturation level: below 90 does not participate in another trial least basic literacy

Exclusion criteria

Exclusion criteria: Lack of cooperation

Design outcomes

Primary

Measure	Time frame
Having symptoms indicative of cough, shortness of breath, fever. Timepoint: Daily - 14 days after treatment. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAkram Asghari

Ghoum University of Medical Sciences

aasgharii@muq.ac.ir+98 25 3912 2000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026